DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
3.930
-0.010 (-0.25%)
Aug 30, 2024, 4:00 PM EDT - Market closed
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
168.00M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coherus BioSciences | 308.13M |
The Joint | 120.07M |
Sangamo Therapeutics | 12.28M |
Lineage Cell Therapeutics | 6.19M |
Shattuck Labs | 4.12M |
Akso Health Group | 2.41M |
Fractyl Health | 119.00K |
DMAC News
- 24 days ago - DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results - Business Wire
- 4 weeks ago - DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024 - Business Wire
- 7 weeks ago - DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point - Seeking Alpha
- 7 weeks ago - DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire
- 2 months ago - DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement - Business Wire
- 2 months ago - DiaMedica Therapeutics Announces $11.8 Million Private Placement - Business Wire
- 2 months ago - DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia - Business Wire
- 4 months ago - DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript - Seeking Alpha